Quality of Life, Patient-Reported Outcomes, and Extent of Surgery for Patients With Low- and Intermediate-Risk–Differentiated Thyroid Cancer
Menée en Chine auprès de 1 060 patients atteints d'un cancer différencié de la thyroïde présentant un risque faible à intermédiaire de récidive (âge médian : 38 ans), cette étude analyse la qualité de vie liée à la santé après un traitement par thyroïdectomie totale ou par lobectomie thyroïdienne
The optimal extent of surgery for patients with low- and intermediate-risk–differentiated thyroid cancer (DTC) is perhaps the most controversial topic in endocrine surgery. Guidelines endorse total thyroidectomy with radioactive iodine for intermediate-risk disease, total thyroidectomy or lobectomy without radioactive iodine for low-risk cancer measuring 1 to 4 cm, and lobectomy or active surveillance for DTC measuring 1 cm or less. While the controversy initially focused on oncologic outcomes, the core of the debate currently centers on patient-reported outcomes. Data on this topic have been largely retrospective or cross-sectional and often underpowered. The study by Chen and colleagues adds greatly to the literature by reporting the results of a large prospective longitudinal cohort study comparing health-related quality of life (QoL) outcomes following total thyroidectomy and lobectomy.
JAMA Surgery , éditorial, 2020